Literature DB >> 9061267

Optimal management of behavioural disorders associated with dementia.

C A Class1, L Schneider, M R Farlow.   

Abstract

Behavioural disorders occur with great frequency in patients with dementia. They are the major reason for admission of these patients to nursing homes. However, there have been few controlled trials of many of the commonly used drugs to guide therapy. To treat these conditions successfully, an adequate description of target symptoms of the behaviours to be corrected and a thorough investigation to identify precipitating causes are essential. Behavioural problems in dementia patients may results from physical illnesses, adverse drug effects, environmental changes, psychiatric syndromes (i.e. depression, delirium or psychosis) or the dementing illness itself. Therapeutic strategies should address the underlying cause whenever possible. Although pharmacological therapies are commonly employed, their efficacy is often modest and adverse effects can be quite significant. Ongoing reassessments are essential to maximise symptomatic benefits and minimise adverse effects. Several trials with different drugs are often necessary before an effective therapy is found. Anticholinergic adverse effects, which occur commonly with many antipsychotic and antidepressant medications, may worsen the cognitive and memory deficits that form the primary symptoms of dementia in these patients. This article summarises the use of the various psychoactive medications that target common behavioural disturbances, including agitation, psychosis, depression and sleep disturbances, in dementia patients. General guidelines regarding dosage, potential adverse effects and duration of therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061267     DOI: 10.2165/00002512-199710020-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  59 in total

1.  Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease.

Authors:  A Satlin; L Volicer; V Ross; L Herz; S Campbell
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

2.  The prevalence and management of dementia and other psychiatric disorders in nursing homes.

Authors:  B W Rovner; P S German; J Broadhead; R K Morriss; L J Brant; J Blaustein; M F Folstein
Journal:  Int Psychogeriatr       Date:  1990       Impact factor: 3.878

3.  Efficacy of antipsychotic medications in behaviorally disturbed dementia patients.

Authors:  R Barnes; R Veith; J Okimoto; M Raskind; G Gumbrecht
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

4.  Diagnostic evaluation of 200 elderly outpatients with suspected dementia.

Authors:  E B Larson; B V Reifler; S M Sumi; C G Canfield; N M Chinn
Journal:  J Gerontol       Date:  1985-09

5.  Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls.

Authors:  T Sunderland; H Weingartner; R M Cohen; P N Tariot; P A Newhouse; K E Thompson; B A Lawlor; E A Mueller
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.

Authors:  P N Tariot; R M Cohen; T Sunderland; P A Newhouse; D Yount; A M Mellow; H Weingartner; E A Mueller; D L Murphy
Journal:  Arch Gen Psychiatry       Date:  1987-05

7.  Open-trial response to antidepressant treatment in elderly patients with mixed depression and cognitive impairment.

Authors:  C F Reynolds; J M Perel; D J Kupfer; B Zimmer; J A Stack; C C Hoch
Journal:  Psychiatry Res       Date:  1987-06       Impact factor: 3.222

8.  A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.

Authors:  S H Shaw; H Curson; J P Coquelin
Journal:  J Int Med Res       Date:  1992-04       Impact factor: 1.671

9.  Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis.

Authors:  S A Factor; D Brown; E S Molho; G D Podskalny
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910

10.  Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings.

Authors:  C Steele; M J Lucas; L Tune
Journal:  J Clin Psychiatry       Date:  1986-06       Impact factor: 4.384

View more
  6 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.

Authors:  N Bhana; C M Spencer
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

4.  Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome.

Authors:  James A Bourgeois; Jennifer B Cogswell; David Hessl; Lin Zhang; Michele Y Ono; Flora Tassone; Faraz Farzin; James A Brunberg; Jim Grigsby; Randi J Hagerman
Journal:  Gen Hosp Psychiatry       Date:  2007 Jul-Aug       Impact factor: 3.238

5.  Psychotropic medication use in canadian long-term care patients referred for psychogeriatric consultation.

Authors:  Corinne E Fischer; Carole Cohen; Lauren Forrest; Tom A Schweizer; Donald Wasylenki
Journal:  Can Geriatr J       Date:  2011-11-11

6.  A non-pharmacological intervention to manage behavioral and psychological symptoms of dementia and reduce caregiver distress: design and methods of project ACT3.

Authors:  Laura N Gitlin; Laraine Winter; Marie P Dennis; Walter W Hauck
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.